Abstract:The CDKN2A/B genomic locus is associated with risk of human cancers and metabolic disease. Although the locus contains several important protein-coding genes, studies suggest disease roles for a lesser-known antisense lncRNA encoded at this locus, called ANRIL. ANRIL is a complex gene containing at least 21 exons in simians, with many reported linear and circular isoforms. Like other genes, abundance of ANRIL is regulated by epigenetics, classic transcription regulation, splicing, and post-transcriptional influences such as RNA stability and microRNAs. Known molecular functions of ANRIL include in cis and in trans gene regulation through chromatin modification complexes, and influence over microRNA signaling networks. Polymorphisms at the ANRIL gene are linked to risk for many different cancers, as well as risk of atherosclerotic cardiovascular disease, bone mass, obesity and type 2 diabetes. A broad array of variable reported impacts of polymorphisms on ANRIL abundance, splicing and function suggests that ANRIL has cell-type and context-dependent regulation and actions. In cancer cells, ANRIL gain of function increases proliferation, metastasis, cell survival and epithelial-mesenchymal transformation, whereas ANRIL loss of function decreases tumor size and growth, invasion and metastasis, and increases apoptosis and senescence. In metabolic disease, polymorphisms at the ANRIL gene are linked to risk of type 2 diabetes, coronary artery disease, coronary artery calcium score, myocardial infarction, and stroke. Intriguingly, with the exception of one polymorphism in exon 2 of ANRIL, the single nucleotide polymorphisms (SNPs) associated with atherosclerosis and diabetes are non-overlapping. Evidence suggests that ANRIL gain of function increases atherosclerosis; in diabetes, a risk-SNP reduced the pancreatic beta cell proliferation index. Studies are limited by the uncertain relevance of rodent models to ANRIL studies, since most ANRIL exons do not exist in mouse. Diverse cell-type-dependent results suggest it is necessary to perform studies in the relevant primary human tissue for each disease. Much remains to be learned about the biology of ANRIL in human health and disease; this research area may lead to insight into disease mechanisms and therapeutic approaches.

ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

Long Noncoding RNA ANRIL Could Be Transactivated by C-Myc and Promote Tumor Progression of Non-Small-cell Lung Cancer.

Long Non-Coding Rna Anril Promotes Tumorigenesis In Glioma Via Mapk Signaling Pathways

Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.

Identification of anoikis-related lncRNAs and analysis of immune infiltration in patients with breast cancer

ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease

LncRNA-ANRIL Promotes Gastric Cancer Progression by Enhancing NF-kB Signaling.

Long non-coding RNA ANRIL promotes tumorgenesis through regulation of FGFR1 expression by sponging miR-125a-3p in head and neck squamous cell carcinoma.

Erratum To: Long Non-Coding RNA ANRIL is Upregulated in Hepatocellular Carcinoma and Regulates Cell Proliferation by Epigenetic Silencing of KLF2

ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer

Long Noncoding RNA ANRIL As a Novel Biomarker of Lymph Node Metastasis and Prognosis in Human Cancer: a Meta-Analysis

Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression

Abstract 157: LncRNA ANRIL Indicates a Potential Prognostic Biomarker in Gastric Cancer and Promotes Tumor Growth by Silencing of Mir-99A/mir-449a

Characterization of novel LncRNA P14AS as a protector of ANRIL through AUF1 binding in human cells

The Long Non-Coding RNA ANRIL Promotes Proliferation and Cell Cycle Progression and Inhibits Apoptosis and Senescence in Epithelial Ovarian Cancer

ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture

New Insights into LINC00346 and its Role in Disease

ANRIL promotes the regulation of colorectal cancer on lymphatic endothelial cells via VEGF-C and is the key target for Pien Tze Huang to inhibit cancer metastasis

Supplementary Figure 1 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression

Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma